Utilization and expenditures for GLP-1 weight loss drugs continue to increase quarter over quarter. With the new FDA approved indication to reduce the risk of major cardiovascular events for Wegovy, DMAS expects that trend may continue to grow. Direct patient advertising campaigns by the pharmaceutical industry continue to drive increases in market share. The drugs are now readily available in the marketplace, elevating prior drug shortages.

Utilization and expenditures for GLP-1 diabetic drugs have stayed consistent over the last two quarters of SFY 2024.

In August 2024, DMAS has implemented the new Body Mass Index (BMI) criteria for weight loss GLP-1 medications as mandated by the General Assembly. DMAS will monitor utilization and expenditures to measure the impact of these changes.